Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01884233 · ClinicalTrials.gov registry record · NA

Cell Phone Technology Targeting ART Adherence and Drug Use

A NA study of HIV and Opioid Abuse, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
62
Enrollment target
1
Study location

NCT01884233 is a NA study of HIV and Opioid Abuse that has completed, run by University of California, Los Angeles. The registered enrollment target is 62 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01884233, a NA study of HIV and Opioid Abuse, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
62 participants
Enrollment target
1
Study location

Study Summary

The objective of the current research is to improve treatment for injection opioid users by augmenting pharmacotherapy with an innovative text-messaging strategy to promote relapse prevention skills, reduce HIV-risk behaviors, and improve HIV treatment regimen adherence.

Conditions Studied

Interventions

  • BEHAVIORAL Standard Care
  • BEHAVIORAL Text Messaging CBT (TXT-CBT)

Study Locations (1)

California

  • UCLA Isap Ocrc - Los Angeles

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2012-12
Est. Completion 2016-01
Phase NA

What the Registry Record Tells You About NCT01884233

The ClinicalTrials.gov registry entry for NCT01884233 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Standard Care is the first listed.

NCT01884233 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01884233 about?

NCT01884233 is a clinical study titled "Cell Phone Technology Targeting ART Adherence and Drug Use". The objective of the current research is to improve treatment for injection opioid users by augmenting pharmacotherapy with an innovative text-messaging strategy to promote relapse prevention skills, reduce HIV-risk behaviors, and improve HIV treatment regimen adherence.

What is the current status of trial NCT01884233?

This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2012-12. Estimated completion is 2016-01.

What conditions does trial NCT01884233 study?

This clinical trial studies the following conditions: HIV, Opioid Abuse.

What interventions are being tested in trial NCT01884233?

The interventions under investigation include: Standard Care (BEHAVIORAL), Text Messaging CBT (TXT-CBT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT01884233?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01884233 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.